Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesa Laboratories (MLAB) Asset Writedowns and Impairment (2017 - 2019)

Mesa Laboratories' Asset Writedowns and Impairment history spans 4 years, with the latest figure at $274.5 million for Q1 2024.

  • For Q1 2024, Asset Writedowns and Impairment changed N/A year-over-year to $274.5 million; the TTM value through Mar 2024 reached $279.6 million, changed N/A, while the annual FY2024 figure was $274.5 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q1 2024 was $274.5 million at Mesa Laboratories, up from $276000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $274.5 million in Q1 2024 and bottomed at $274.5 million in Q1 2024.